Intratumoral N17350 in Advanced Solid Tumors

Summary

The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies. The main questions it aims to answer are: Does N17350 cause tumors to shrink or stop growing in some participants with advanced solid tumors? Are there any side effects for participants when taking N17350? What is the safest dose of N17350 and the dose that should be used for further study? Researchers will give N17350 directly into tumor lesions using a needle (intratumoral injection).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Neoplasms, Solid Tumor
• Breast Neoplasms, Triple-Negative
• Squamous Cell Carcinoma of Skin
• Melanoma
• Head and Neck Neoplasms
• Carcinoma, Squamous Cell
• Carcinoma, Non-Small-Cell Lung

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Onchilles Pharma Inc

Last updated on ClinicalTrials.gov

September 23, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites